Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.
Haemonetics Corporation today announced the release of its 2022 Corporate Responsibility Report.
Haemonetics Publishes Inaugural Corporate Responsibility Report Read More »
Promore Pharma In the light of the publication of the results from the clinical trial PHSU05, Promore Pharma AB invites to a webcast on Friday 21 April kl 10.00
Invitation to a Presentation of the Results from Promore Pharma’s Clinical Trial PHSU05 Read More »
Immunovia announced it will participate in a webinar titled “Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer” hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.
Promore Pharma AB announces that the results from the company’s Phase II study PHSU05 with ensereptide in prevention of skin scarring have been concluded.
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide Read More »
OSE Immunotherapeutics SA presented two additional posters reporting the latest research updates on CLEC-1, from its Myeloid platform, at the 2023 American Association for Cancer Research Annual Meeting held in Orlando on April 14-19.
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
InnoCare Pharma, a leading biopharmaceutical company, announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma.
Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta® had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta.
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2023.
Hansa Biopharma interim report January-March 2023 Read More »
